132871-11-5

Basic information

• Product Name: 1-BENZYL-3(R)-METHYL-PIPERAZINE
• Synonyms: 1-BENZYL-3(R)-METHYL-PIPERAZINE;4-BENZYL-2-(R)-METHYLPIPERAZINE;(R)-2-METHYL-4-BENZYLPIPERAZINE;Piperazine, 3-methyl-1-(phenylmethyl)-, (3R)- (9CI);(3R)-1-BENZYL-3-METHYLPIPERAZINE;4-BENZYL-2--METHYLPIPERAZINE;(3R)-3-Methyl-1-(phenylmethyl)piperazine;(R)-3-Methyl-1-(phenylmethyl)piperazine
• CAS NO: 132871-11-5
• Molecular Formula: C₁₂H₁₈N₂
• Molecular Weight: 190.28
• Product Categories: PIPERIDINE;pharmacetical
• Mol File: 132871-11-5.mol
• Article Data: 8

Chemical Properties

• Melting Point: 30-32 °C
• Boiling Point: 281℃
• Flash Point: 112℃
• Appearance: /
• Density: 0.991
• Vapor Pressure: 0.00354mmHg at 25°C
• Refractive Index: 1.529
• PKA: 9.31±0.40(Predicted)
• CAS DataBase Reference: 1-BENZYL-3(R)-METHYL-PIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BENZYL-3(R)-METHYL-PIPERAZINE(132871-11-5)
• EPA Substance Registry System: 1-BENZYL-3(R)-METHYL-PIPERAZINE(132871-11-5)

Safety Data

• Hazardous Substances Data: 132871-11-5(Hazardous Substances Data)

Usage

General Description

1-Benzyl-3(R)-methyl-piperazine is a chemical compound that belongs to the piperazine class of organic compounds. It is a derivative of piperazine and has a benzyl group attached to the nitrogen atom, as well as a methyl group on the third carbon atom. 1-Benzyl-3(R)-methyl-piperazine has potential pharmacological properties and may be used in the development of pharmaceutical drugs. It has been studied for its potential as a central nervous system stimulant and as an antipsychotic agent. Additionally, it has been investigated for its potential as a treatment for conditions such as depression, anxiety, and schizophrenia. Research on 1-Benzyl-3(R)-methyl-piperazine continues to explore its potential therapeutic uses and effects on the body.

InChI:InChI=1/C12H18N2/c1-11-9-14(8-7-13-11)10-12-5-3-2-4-6-12/h2-6,11,13H,7-10H2,1H3/t11-/m1/s1

Upstream product

• 174799-52-1 tert-butyl {2-[benzylamino]ethyl}carbamate 
• 100-52-7 benzaldehyde 
• 3138-90-7 3-methyl-1-(phenylmethyl)piperazine 
• 75336-86-6 (2R)-methylpiperazine 
• 100-39-0 benzyl bromide 
• 104-63-2 N-Benzylethanolamine 
• 170033-53-1 (R)-<2-<(2-Hydroxyethyl)(phenylmethyl)amino>-1-methyl-2-oxoethyl>carbamic acid 1,1-dimethylethyl ester 
• 170033-65-5 (R)-2-Amino-N-benzyl-N-(2-hydroxy-ethyl)-propionamide 
• 153842-01-4 (R)-2-(2-Chloro-acetylamino)-propionic acid methyl ester 
• 100-44-7 benzyl chloride 
• 132871-09-1 (R)-1-benzyl-3-methylpiperazine-2,5-dione 
• 170033-55-3 (R)-3-Methyl-1-(phenylmethyl)piperazin-2-one 

Downstream Products

• 945027-28-1 C₁₄H₁₉N₂OCl 
• 511255-22-4 4-(4-chloro-phenyl)-3-(R)-methyl-piperazine 
• 825644-79-9 (R)-N-[6-(4-benzyl-2-methyl-piperazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide 
• 1346555-42-7 (R)-tert-butyl 2-(4-benzyl-2-methylpiperazin-1-yl)pyrimidine-4-carboxylate 
• 740806-52-4 4-Benzyl-1-(4-chloro-3-methoxy-phenyl)-2-(R)-methyl-piperazine 
• 260254-66-8 1-N-[2-(R)-methylpiperazine]-3,4,5-trimethoxybenzamide 
• 170033-47-3 (R)-tert-butyl 2-methylpiperazine-1-carboxylate 
• 75336-86-6 (2R)-methylpiperazine 
• 511255-18-8 (R)-4-benzyl-1-(4-chlorophenyl)-2-methylpiperazine 
• 400785-79-7 1R-[4-(4-benzyl-2R-methyl-piperazin-1-yl)pyrimidin-2-yl]ethyl butyrate 
• 400785-83-3 (R)-4-benzyl-2-methyl-piperazine-1-N,N'-bis(tert-butoxycarbonyl)carboxamidine 
• 260254-64-6 1-N-[2-(R)-methyl-4-benzylpiperazine]-3,4,5-trimethoxybenzamide 
• 170033-58-6 tert-Butyl (R)-2-methyl-4-(phenylmethyl)-1-piperazinecarboxylate 

Relevant articles and documents

Catalytic Asymmetric Synthesis of Morpholines. Using Mechanistic Insights to Realize the Enantioselective Synthesis of Piperazines

An efficient and practical catalytic approach for the enantioselective synthesis of 3-substituted morpholines through a tandem sequential one-pot reaction employing both hydroamination and asymmetric transfer hydrogenation reactions is described. Starting from ether-containing aminoalkyne substrates, a commercially available bis(amidate)bis(amido)Ti catalyst is utilized to yield a cyclic imine that is subsequently reduced using the Noyori-Ikariya catalyst, RuCl [(S,S)-Ts-DPEN] (η6-p-cymene), to afford chiral 3-substituted morpholines in good yield and enantiomeric excesses of >95%. A wide range of functional groups is tolerated. Substrate scope investigations suggest that hydrogen-bonding interactions between the oxygen in the backbone of the ether-containing substrate and the [(S,S)-Ts-DPEN] ligand of the Ru catalyst are crucial for obtaining high ee's. This insight led to a mechanistic proposal that predicts the observed absolute stereochemistry. Most importantly, this mechanistic insight allowed for the extension of this strategy to include N as an alternative hydrogen bond acceptor that could be incorporated into the substrate. Thus, the catalytic, enantioselective synthesis of 3-substituted piperazines is also demonstrated.

GLYCINE TRANSPORTER-1 INHIBITORS

The present invention provides compounds that are glycine transporter 1 (hereinafter referred to as GlyT-1) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of GlyT1 such as cognitive disorders associated with Schizophrenia, ADHD (attention deficit hyperactivity disorder), MCI (mild cognitive impairment), and the like. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

DUAL NK1/NK3 ANTAGONISTS FOR TREATING SCHIZOPHRENIA

The use of compounds of the general formula wherein the substituents are as described in claim 1 or pharmaceutically active acid-addition salts thereof for the preparation of medicaments for the treatment of schizophrenia.